---
subject: Newsletter Vol.151 - March 2017
---

{{> header-secondary }}

<wrapper class="header header-primary">
	<container>
		<row class="collapse">
			<columns small="12" large="6" valign="middle">
				<img class="logo logo-ddc small-float-center" src="https://media.drugs.com/wp-content/uploads/2017/12/logo-ddc.png" width="212" height="44" alt="Drugs.com">
			</columns>
			<columns small="12" large="6">
				<p class="small-text-center text-right no-space" valign="middle">
					<span class="header-title">Monthly News Roundup</span><br>
					<span class="header-sub-title">Vol 151, March 2017</span>
				</p>
			</columns>
		</row>
	</container>
</wrapper>

<container>
	
	<row>
		<columns small="12">
			<h2>Featured News</h2>
			<p>A wide range of ailments gain new treatments in March. Genentech’s Ocrevus, a novel agent for two forms of MS is cleared, as is Regeneron’s Dupixent for more severe cases of eczema. A new PARP inhibitor, Zejula, is added to the arsenal for ovarian cancer, and oral Kisqali from Novartis targets HR+/HER2- metastatic breast cancer. Rounding out the month, Xadago is given the go-ahead to treat "off" episodes in Parkinson’s disease.</p>
			<button href="#" class="radius btn-offset">Read More</button>
		</columns>
	</row>
	
	<row class="row-spacer">
		<columns small="12"></columns>
	</row>
	
	<row>
		<columns small="12">
			<h2 class="header-trim">New Drug Approvals</h2>
			<p class="sub-header text-muted">The following drugs have recently been approved by the FDA.</p>
			<ul class="list-featured list-unstyled">
				<li>
					<a href="#">Dupixent (dupilumab) Injection</a>
					<p>Date of Approval: March 28, 2017<br>
					Treatment for: Atopic Dermatitis.</p>
				</li>
				<li>
					<a href="#">Ocrevus (ocrelizumab) Injection</a>
					<p>Date of Approval: March 28, 2017</p>
					<p>Treatment for: Atopic Dermatitis.</p>
				</li>
				<li>
					<a href="#">Zejula (niraparib) Capsules</a>
					<p>Date of Approval: March 28, 2017</p>
					<p>Treatment for: Atopic Dermatitis.</p>
				</li>
				<li>
					<a href="#">Bavencio (avelumab) Injection</a>
					<p>Date of Approval: March 28, 2017<br>
					Treatment for: Atopic Dermatitis.</p>
				</li>
				<li>
					<a href="#">Symproic (naldemedine) Tablets</a>
					<p>Date of Approval: March 28, 2017</p>
					<p>Treatment for: Atopic Dermatitis.</p>
				</li>
			</ul>
			<button href="#" class="radius btn-offset">More Drug Approvals</button>
		</columns>
	</row>

	<row class="collapse sponsored">
		<columns small="12">
			<callout class="primary">
				<p class="header-label text-uppercase">Sponsored Content</p>
				<ul class="list-pull-left">
					<li>
						<a href="#">Site For Endocrinologists</a><br>
						Low Testosterone Due To Certain Medical Conditions. Treatment Info
					</li>
					<li>
						<a href="#">HCP Site - Relapsing MS Medication Info</a><br>
						View Information On An Oral Treatment For Relapsing MS. Sign Up For Updates
					</li>
					<li>
						<a href="#">Help Prevent Next Heart Attack - A Proven Treatment Option</a><br>
						Learn About A Heart Attack Treatment Indicated To Help Prevent A Second Attack
					</li>
				</ul>
			</callout>
		</columns>
	</row>

	<row>
		<columns small="12">
			<h2 class="header-trim">New Indications and Dosage Forms</h2>
			<p class="sub-header text-muted">Drugs that have gained FDA approval for the treatment of additional diseases/conditions or new dosage forms/regimens.</p>
			<ul class="list-featured list-unstyled">
				<li>
					<a href="#">Humira (adalimumab) Injection</a>
					<p>Labeling Revision Approved: March 27, 2017<br>
					Now Approved: Addition of Fingernail Psoriasis Data to Prescribing Information.</p>
				</li>
				<li>
					<a href="#">Juvederm (dermal filler)</a>
					<p>New Formulation Approved: March 20, 2017<br>
					Now Approved: Juvéderm Vollure XC</p>
				</li>
				<li>
					<a href="#">Keytruda (pembrolizumab) for Injection</a>
					<p>New Indication Approved: March 14, 2017<br>
					Now Approved for: Classical Hodgkin Lymphoma</p>
				</li>
			</ul>
			<button href="#" class="radius btn-offset">Read More</button>
		</columns>
	</row>

	<row>
		<columns small="12">
			<hr/>
			<h2 class="header-trim">First-Time Generic Approvals</h2>
			<p class="sub-header text-muted">First Time Generics are those drug products that have never been approved before as generic drug products and are new generic products to the marketplace.</p>
			<ul class="list-featured list-unstyled">
				<li>
					<a href="#">Zileuton Extended Release Tablets</a>
					<p><strong>600 mg</strong><br>
					Approved: March 17, 2017 - Pack Pharmaceuticals, LLC<br>
					Generic for: Zyflo CR.</p>
				</li>
			</ul>
			<button href="#" class="radius btn-offset">Read Approvals</button>
		</columns>
	</row>

	<row>
		<columns small="12">
			<hr/>
			<h2 class="header-trim">Other Drug News</h2>
			<ul class="list-secondary list-unstyled">
				<li><a href="#">Common Post-Op Ear Drops Tied to Eardrum Perforations in Kids</a></li>
				<li><a href="#">Got the HPV Vaccine Before You Knew You Were Pregnant? Don't Worry</a></li>
				<li><a href="#">High Doses of Vitamin D Fail to Cut Cancer Risk, Study Finds</a></li>
				<li><a href="#">Study Suggests Heartburn Meds-Superbug Infections Link</a></li>
				<li><a href="#">What Drugs Work Best for Diabetic Nerve Pain?</a></li>
				<li><a href="#">Drug No Better Than Placebo for Lower Back, Leg Pain</a></li>
			</ul>
			<button href="#" class="radius btn-offset">More Updates</button>
		</columns>
	</row>

	<row class="row-spacer">
		<columns small="12"></columns>
	</row>

	<row class="row-fda">
		<columns small="12">
			<spacer size="30"></spacer>
			<center>
				<img class="logo-fda" src="https://media.drugs.com/wp-content/uploads/2017/12/logo-fda.png" alt="U S Food and Drug Administration" width="250" height="60">
			</center>
			<spacer size="20"></spacer>
		</columns>
	</row>
	<row>
		<columns small="12" large="6">
			<p class="header-label text-uppercase">MedWatch Alerts</p>
			<ul class="list-secondary list-unstyled">
				<li>
					<a href="#">LaBri’s Body Health Atomic by Envy Me: Recall - Undeclared Drug Ingredient</a>
				</li>
				<li>
					<a href="#">Breast Implants: Update - Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)</a>
				</li>
				<li>
					<a href="#">Drug Safety Communication: Viberzi (eluxadoline) - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder</a>
				</li>
			</ul>
			<a href="#">More MedWatch Alerts</a>
			<div class="hide-for-large">
				<spacer size="10"></spacer>
				<hr>
			</div>
		</columns>
		<columns small="12" large="6">
			<p class="header-label text-uppercase">Consumer Updates</p>
			<ul class="list-secondary list-unstyled">
				<li><a href="#">Depression: FDA-Approved Medications May Help</a></li>
				<li><a href="#">Dealing with ADHD: What You Need to Know</a></li>
				<li><a href="#">Making Decisions for Your Health: Getting the Info You Need</a></li>
				<li><a href="#">FDA: Cutting-Edge Technology Sheds Light on Antibiotic Resistance</a></li>
			</ul>
			<a href="#">More Consumer Updates</a>
		</columns>
	</row>
	<row>
		<columns small="12">
			<spacer size="10"></spacer>
		</columns>
	</row>

	<row class="row-spacer">
		<columns small="12"></columns>
	</row>

	<row class="row-trim-columns">
		<columns small="12">
			<h2>Tools &amp; Helpful Links</h2>
		</columns>
	</row>
	<row class="row-trim-columns">
		<columns small="12" large="6">
			<ul class="list-secondary list-unstyled">
				<li><a href="#">Interactions Checker</a></li>
				<li><a href="#">Compare Drugs</a></li>
				<li><a href="#">News &amp; Alerts</a></li>
			</ul>
		</columns>
		<columns small="12" large="6">
			<ul class="list-secondary list-unstyled">
				<li><a href="#">Pill Identifier</a></li>
				<li><a href="#">Medical Q &amp; A</a></li>
				<li><a href="#">My Med List</a></li>
			</ul>
		</columns>
	</row>

	<row>
		<columns small="12">
			<spacer size="10"></spacer>
			<p class="text-secondary text-medium text-muted">This information is not intended to be medical advice. You should contact your physician before making any changes to your health care. Drugs.com is not responsible for content provided by third-party websites.</p>
			<p class="text-secondary text-medium text-muted">We always appreciate feedback so if you wish to give us your comments/ praise/ rebuke please Contact Us.</p>
			<p class="text-secondary text-medium text-muted">Thanks so much for your continued support!</p>
			<p class="text-secondary text-medium text-muted">The Editorial Team<br>Drugs.com</p>
		</columns>
	</row>

</container>

{{> footer }}